SG
AMRX icon

Straightline Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Straightline Group’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,600
Closed -$91.9K – 18
2024
Q4 		$91.9K Buy
+11,600
New +$97.3K 0.06% 46

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Straightline Group's AMRX Position: Q1 2025 in Review

Straightline Group sold out of Amneal Pharmaceuticals (AMRX) in Q1 2025, closing a stake of 11,600 shares — an estimated $91.9K sold.

Straightline Group first reported a position in AMRX in Q4 2024 and held it in 1 quarter. The position peaked at $91.9K in Q4 2024. 237 funds tracked by Wall St. Rank hold AMRX as of Q1 2025.

  • Straightline Group reported no remaining Amneal Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Straightline Group sold 11,600 Amneal Pharmaceuticals shares in Q1 2025, an estimated $91.9K.
  • Straightline Group first reported a position in Amneal Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Straightline Group's Amneal Pharmaceuticals position peaked at $91.9K in Q4 2024.
  • 237 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2025.

Based on Straightline Group's 13F filing for Q1 2025, filed 14 May 2025.